Last reviewed · How we verify
Blood and Dopamine
Unknown mechanism; the drug name suggests potential involvement in blood regulation and dopaminergic pathways, but specific molecular action is not established.
At a glance
| Generic name | Blood and Dopamine |
|---|---|
| Also known as | Dopamine, Blood |
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This appears to be an investigational compound in Phase 3 development by the International Centre for Diarrhoeal Disease Research, Bangladesh. The name 'Blood and Dopamine' is non-standard nomenclature and does not correspond to recognized pharmaceutical naming conventions, making mechanistic details unavailable from standard sources.
Approved indications
Common side effects
Key clinical trials
- PET Scanning in Parkinson s Disease
- Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms (PHASE2)
- Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease. (PHASE2)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- The Effect of Family Member Voices on Dopamine, Serotonin Levels, and Pain in Patients in Intensive Care Units (NA)
- Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) (PHASE4)
- The Meaning of Dopaminergic Pathway in Sleep Breathing Disorders.
- Pain, Central Sensitization and Psychoemotional State in Patients With Chronic Masticatory Muscle Pain
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: